PURPOSE: A phase III trial (Cancer and Leukemia Group B CALGB-49907) was conducted to test whether older patients with early-stage breast cancer would have equivalent relapse-free and overall survival with capecitabine compared with standard chemotherapy. The quality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better QoL than standard chemotherapy. PATIENTS AND METHODS: QoL was assessed in 350 patients randomly assigned to eitherstandard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil [CMF] or doxorubicin and cyclophosphamide [AC]; n = 182) or capecitabine (n = 168). Patients were interviewed by telephone before treatment (baseline), midtreatment, within 1 month post-treatment, and at 12, 18, and 24 months postbaseline by using questionnaires from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), a breast systemic adverse effects scale (EORTC BR23), and the Hospital Anxiety and Depression Scale (HADS). RESULTS: Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P ≤ .005). Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P ≤ .004), but worse hand-foot syndrome and diarrhea (P < .005). These differences all resolved by 12 months. CONCLUSION:Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer. Although capecitabine was associated with better QoL during treatment, QoL was similar for both groups at 1 year. The brief period of poorer QoL with standard treatment is a modest price to pay for a chance at improved survival.
RCT Entities:
PURPOSE: A phase III trial (Cancer and Leukemia Group B CALGB-49907) was conducted to test whether older patients with early-stage breast cancer would have equivalent relapse-free and overall survival with capecitabine compared with standard chemotherapy. The quality of life (QoL) substudy tested whether capecitabine treatment would be associated with a better QoL than standard chemotherapy. PATIENTS AND METHODS: QoL was assessed in 350 patients randomly assigned to either standard chemotherapy (cyclophosphamide, methotrexate, and fluorouracil [CMF] or doxorubicin and cyclophosphamide [AC]; n = 182) or capecitabine (n = 168). Patients were interviewed by telephone before treatment (baseline), midtreatment, within 1 month post-treatment, and at 12, 18, and 24 months postbaseline by using questionnaires from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), a breast systemic adverse effects scale (EORTC BR23), and the Hospital Anxiety and Depression Scale (HADS). RESULTS: Compared with patients who were treated with standard chemotherapy, patients who were treated with capecitabine had significantly better QoL, role function, and social function, fewer systemic adverse effects, less psychological distress, and less fatigue during and at the completion of treatment (P ≤ .005). Capecitabine treatment was associated with less nausea, vomiting, and constipation and with better appetite than standard treatment (P ≤ .004), but worse hand-foot syndrome and diarrhea (P < .005). These differences all resolved by 12 months. CONCLUSION: Standard chemotherapy was superior to capecitabine in improving relapse-free and overall survival for older women with early-stage breast cancer. Although capecitabine was associated with better QoL during treatment, QoL was similar for both groups at 1 year. The brief period of poorer QoL with standard treatment is a modest price to pay for a chance at improved survival.
Authors: M A Sprangers; M Groenvold; J I Arraras; J Franklin; A te Velde; M Muller; L Franzini; A Williams; H C de Haes; P Hopwood; A Cull; N K Aaronson Journal: J Clin Oncol Date: 1996-10 Impact factor: 44.544
Authors: J A Oshaughnessy; J Blum; V Moiseyenko; S E Jones; D Miles; D Bell; R Rosso; L Mauriac; B Osterwalder; H U Burger; S Laws Journal: Ann Oncol Date: 2001-09 Impact factor: 32.976
Authors: L R Derogatis; G R Morrow; J Fetting; D Penman; S Piasetsky; A M Schmale; M Henrichs; C L Carnicke Journal: JAMA Date: 1983-02-11 Impact factor: 56.272
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Hyman B Muss; Donald A Berry; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford A Hudis; Eric P Winer Journal: N Engl J Med Date: 2009-05-14 Impact factor: 91.245
Authors: A J Saykin; R S Janssen; G C Sprehn; J E Kaplan; T J Spira; B O'Connor Journal: J Neuropsychiatry Clin Neurosci Date: 1991 Impact factor: 2.198
Authors: C W Wallwiener; A D Hartkopf; E Grabe; M Wallwiener; F-A Taran; T Fehm; S Y Brucker; B Krämer Journal: J Cancer Res Clin Oncol Date: 2016-06-27 Impact factor: 4.553
Authors: Trevor A Jolly; Allison M Deal; Caroline Mariano; Nicole Markowski; Sharanda Kirk; Max S Perlmutt; Franklin Jones; Suel Ki Choi; Kirsten A Nyrop; Jan Busby-Whitehead; Hyman Muss Journal: Oncologist Date: 2020-01-27
Authors: Judith O Hopkins; Jake Allred; Arti Hurria; Aminah Jatoi; Jacqueline M Lafky; Harvey Cohen; Clifford Hudis; Eric Winer; Jeanne Mandelblatt; Ann Partridge; Lisa Carey; Hyman B Muss Journal: Breast Cancer Res Treat Date: 2017-08-20 Impact factor: 4.872
Authors: Arti Hurria; Enrique Soto-Perez-de-Celis; Jacob B Allred; Harvey Jay Cohen; Anait Arsenyan; Karla Ballman; Jennifer Le-Rademacher; Aminah Jatoi; Julie Filo; Jeanne Mandelblatt; Jacqueline M Lafky; Gretchen Kimmick; Heidi D Klepin; Rachel A Freedman; Harold Burstein; Julie Gralow; Antonio C Wolff; Gustav Magrinat; Myra Barginear; Hyman Muss Journal: J Am Geriatr Soc Date: 2018-08-26 Impact factor: 5.562
Authors: Marloes G M Derks; Nienke A de Glas; Esther Bastiaannet; Anton J M de Craen; Johanneke E A Portielje; Cornelis J H van de Velde; Floor E van Leeuwen; Gerrit-Jan Liefers Journal: Oncologist Date: 2016-07-01
Authors: Jeanne S Mandelblatt; Solomon B Makgoeng; Gheorghe Luta; Arti Hurria; Gretchen Kimmick; Claudine Isaacs; Michelle Tallarico; William T Barry; Brandy Pitcher; Eric P Winer; Clifford Hudis; Harvey J Cohen; Hyman B Muss Journal: J Geriatr Oncol Date: 2013-06-20 Impact factor: 3.599